Axiom Bio is a Florida-based biotechnology startup developing novel rescue and stabilization therapies for opioid overdose patients. Founded in 2025 and currently patent pending, our company was built on the urgent need to go beyond naloxone, to not only reverse overdose, but to stabilize patients through the critical window that follows.

Our lead candidate, AXM-101, is a dual-phase injectable combining rapid-release naloxone with delayed-release mitragynine, a partial agonist designed to ease withdrawal and reduce relapse risk. This delivery system, encapsulated in biodegradable microparticles, aims to close the life-threatening gap between initial revival and true recovery.

We are in our earliest stages, securing lab access, materials, and formulation support but our vision is clear: a future where overdose reversal doesn't end in relapse or tragedy, but in a real second chance. Axiom Bio is based in Gainesville, FL and proudly driven by first-generation founders, science-backed design, and a deep commitment to public health innovation.